1978
Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma
Johnson B, Fisher R, Bender R, Devita V, Chabner B, Young R. Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma. Cancer 1978, 42: 2157-2161. PMID: 102417, DOI: 10.1002/1097-0142(197811)42:5<2157::aid-cncr2820420511>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsDose modificationOvarian cancerDiscontinuation of therapyAdvanced ovarian cancerMedian durationObjective responseAgent therapyProspective studyOvarian carcinomaDay courseSevere toxicityPatientsAttractive agentTherapyToxic effectsHexamethylmelamineCancerDegree of toxicityToxicityActive agentsDiscontinuationChemotherapyNeurologicCarcinomaHematologic
1973
Streptozotocin for Malignant Insulinomas and Carcinoid Tumor: Report of Eight Cases and Review of the Literature
Schein P, Kahn R, Gorden P, Wells S, DeVita V. Streptozotocin for Malignant Insulinomas and Carcinoid Tumor: Report of Eight Cases and Review of the Literature. JAMA Internal Medicine 1973, 132: 555-561. DOI: 10.1001/archinte.1973.03650100069013.Peer-Reviewed Original ResearchMalignant insulinomaBone marrow depressionDrug dose levelsPeak serum concentrationComplete remissionMarrow depressionMetastatic insulinomaObjective responseCarcinoid tumorsMalignant carcinoidSerum concentrationsInfusion rateLow doseStreptozotocinDose levelsInjection sitePatientsInsulinomaLimited responseRemissionCarcinoidsResponseChemotherapyPainTumors
1972
Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously.
Bagley C, Canellos G, Young R, Gallelli J, Devita V. Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously. Cancer Chemotherapy Reports 1972, 56: 387-91. PMID: 19051499.Peer-Reviewed Original ResearchConceptsClinical trialsDose-limiting toxic effectPhase II trialBone marrow toxicityConsecutive daily injectionsTime of onsetDegree of severitySevere nauseaII trialObjective responseDaily injectionsMarrow toxicityPatientsTrialsToxic effectsToxicityNauseaVomitingPainLymphomaMelanomaTumorsLymphosarcomaAdministrationDose